Last reviewed · How we verify
FF/VI via ELLIPTA DPI
FF/VI is a combination of fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation for chronic obstructive pulmonary disease.
FF/VI is a combination of fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation for chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy.
At a glance
| Generic name | FF/VI via ELLIPTA DPI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (fluticasone furoate); beta-2 adrenergic receptor (vilanterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate acts as a potent inhaled corticosteroid that suppresses inflammatory responses in the airways, while vilanterol is a long-acting beta-2 agonist that stimulates beta-2 adrenergic receptors to promote bronchial smooth muscle relaxation and sustained airway opening. The combination provides both anti-inflammatory and bronchodilatory effects delivered via dry powder inhaler (ELLIPTA) for maintenance therapy.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nasopharyngitis
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design (PHASE4)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
- A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF/VI via ELLIPTA DPI CI brief — competitive landscape report
- FF/VI via ELLIPTA DPI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI